Cristcot NDA Accepted for ngHCA in Ulcerative Colitis
Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...
Alzheimer’s Disease Autoimmune Disease Bio-Pharma biologics biopharma biopharma innovation Biotechnology cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance GCP Gene Therapy GMP Immuno-Oncology immunology Immunotherapy Medical Devices MedTech medtech innovation Monoclonal Antibody NSCLC Oncology oncology innovation Orphan Drug orphan drug designation patient access Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory approval regulatory compliance targeted therapy
Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...
Waltham, Massachusetts | April 10, 2026 Spyre Therapeutics Inc. has announced that it will report topline results from Part...
WILMINGTON, Del., April 2, 2026 Earendil Labs, an AI-driven biotechnology company, has announced that the first patient has been...
STOCKHOLM, Sweden, Feb. 21, 2026 — Johnson & Johnson announced new long-term findings from the QUASAR long-term extension study...
REYKJAVIK, Iceland, Feb. 5, 2026 —Alvotech announced positive top-line results from a pivotal pharmacokinetic (PK) study evaluating AVT80, its...
GHENT, Belgium | January 9, 2026 — MRM Health announced that the U.S. Food and Drug Administration (FDA) has...
Montréal, 28 November 2025 In a major development for inflammatory bowel disease (IBD) care, Canada’s Drug Agency (AMC) has...
HORSHAM, Pa., Sept. 19, 2025 — Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug...
